The T cell receptor (TCR) signaling pathway is an ensemble of numerous proteins that are crucial for an adequate immune response. Disruption of any protein involved in this pathway leads to severe immunodeficiency and unfavorable clinical outcomes. Here, we describe an infant with severe immunodeficiency who was found to have novel biallelic mutations in SLP76. SLP76 is a key protein involved in TCR signaling and in other hematopoietic pathways. Previous studies of this protein were performed using Jurkat-derived human leukemic T cell lines and SLP76-deficient mice. Our current study links this gene, for the first time, to a human immunodeficiency characterized by early-onset life-threatening infections, combined T and B cell immunodeficiency, severe neutrophil defects, and impaired platelet aggregation. Hereby, we characterized aspects of the patient's immune phenotype, modeled them with an SLP76-deficient Jurkat-derived T cell line, and rescued some consequences using ectopic expression of wild-type SLP76. Understanding human diseases due to SLP76 deficiency is helpful in explaining the mixed T cell and neutrophil defects, providing a guide for exploring human SLP76 biology.
CD4+ T cells are vital for host defense and immune regulation. However, the fundamental role of CD4 itself remains enigmatic. We report seven patients aged 5–61 years from five families of four ancestries with autosomal recessive CD4 deficiency and a range of infections, including recalcitrant warts and Whipple’s disease. All patients are homozygous for rare deleterious CD4 variants impacting expression of the canonical CD4 isoform. A shorter expressed isoform that interacts with LCK, but not HLA class II, is affected by only one variant. All patients lack CD4+ T cells and have increased numbers of TCRαβ+CD4−CD8− T cells, which phenotypically and transcriptionally resemble conventional Th cells. Finally, patient CD4−CD8− αβ T cells exhibit intact responses to HLA class II–restricted antigens and promote B cell differentiation in vitro. Thus, compensatory development of Th cells enables patients with inherited CD4 deficiency to acquire effective cellular and humoral immunity against an unexpectedly large range of pathogens. Nevertheless, CD4 is indispensable for protective immunity against at least human papillomaviruses and Trophyrema whipplei.
Background: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. Objectives: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. Methods: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. Results: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. Conclusions: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.